|
Canada-0-BAGS Azienda Directories
|
Azienda News:
- Drug Approvals and Databases | FDA
Downloadable data files FDA Adverse Event Reporting System (FAERS) Public Dashboard Inactive Ingredient Search for Approved Drug Products Search More information Medication Guides Search More
- Novel Drug Approvals for 2025 | FDA
FDA Novel Drug Therapy Approvals for 2025 In 2025, CDER approved 46 new drugs never before approved or marketed in the U S , known as “novel” drugs
- This rare disease destroys a childs ability to walk and . . .
After a string of denials for rare disease treatment candidates, the FDA last week greenlit a drug for Hunter syndrome, a progressive illness affecting about 500 Americans
- FDA approves Denali Hunter syndrome drug - fiercepharma. com
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates In approving
- WTAS: FDA Approves Drug to Treat Neurologic Manifestations of . . .
Media round-up on FDA’s approval of Avlayah to treat certain individuals with Hunter syndrome
- New FDA Drug Approvals for 2026 - Drugs. com
Up to date information on the latest FDA drug approvals Includes list of most recent approvals, the conditions approved for, and the approval history
- Search Orphan Drug Designations and Approvals
This page searches the Orphan Drug Product designation database Searches may be run by entering the product name, orphan designation, and dates Results can be displayed as a condensed list, detailed list, or an Excel spreadsheet Click for detailed instructions
- Breaking Through the Rare Disease Barrier: FDA’s Historic . . .
The newly named drug, Avlayah (tividenofusp alfa), as reported by Fierce Pharma, represents the first FDA-approved treatment capable of addressing the neurological complications that devastate Hunter syndrome patients, a rare genetic condition affecting approximately one in 100,000 to 150,000 male births
- UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA . . .
"The FDA approval of UPLIZNA marks a significant turning point for IgG4-RD patients and physicians who now have a proven treatment that targets a key driver of the disease, reducing the risk of flares and reliance on harmful long-term steroid use," said Jay Bradner, M D , executive vice president of Research and Development at Amgen
- FDA-Approved Treatments for Alzheimers
FDA-Approved Drugs For Alzheimer's The FDA has approved medications that fall into two categories: drugs that change disease progression in people living with early Alzheimer's disease, and drugs that may temporarily mitigate some symptoms of Alzheimer's dementia
|
|